Actuate therapeutics announces pricing of initial public offering

Chicago and fort worth, texas, aug. 12, 2024 (globe newswire) -- actuate therapeutics, inc. (nasdaq: actu) (the “company”), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the pricing of its initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public for a total of $22,400,000 of gross proceeds to the company, before deducting underwriting discounts and offering expenses (the “offering”).
ACTU Ratings Summary
ACTU Quant Ranking